revive-therapeutics.png
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
November 30, 2022 17:43 ET | Revive Therapeutics Ltd.
TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum...
revive-therapeutics.png
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 24, 2022 09:18 ET | Revive Therapeutics Ltd.
TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 22, 2022 09:20 ET | Revive Therapeutics Ltd.
TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
October 14, 2022 13:34 ET | Revive Therapeutics Ltd.
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
October 06, 2022 10:18 ET | Revive Therapeutics Ltd.
TORONTO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
September 28, 2022 07:00 ET | Revive Therapeutics Ltd.
TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
September 16, 2022 06:00 ET | Revive Therapeutics Ltd.
TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
September 14, 2022 06:00 ET | Revive Therapeutics Ltd.
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
August 16, 2022 06:00 ET | Revive Therapeutics Ltd.
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
July 25, 2022 10:57 ET | Revive Therapeutics Ltd.
TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...